PREGNANCY OUTCOME FOLLOWING FIRST-TRIMESTER EXPOSURE TO SUMATRIPTAN

We prospectively compared pregnancy outcome after exposure to sumatrip tan with that of disease-matched controls and nonteratogen controls. T here were no differences in the rates of live births, spontaneous abor tions, therapeutic abortions, or major birth defects among the three g roups. This first prospective report suggests that the use of sumatrip tan during organogenesis is not associated with an apparent increased risk of major birth defects.